Drugmakers Delay European Launches Over Trump's Pricing Fears

Key Summary of European Drug Launch Delays

Pharmaceutical companies are postponing the launch of new medicines in Europe. This strategic delay is a direct response to uncertainty surrounding U.S. drug pricing policies proposed by President Donald Trump, particularly the "most-favored-nation" (MFN) approach which could significantly impact global revenue streams.

Overview of the Situation

The core issue is the U.S. administration's push to lower domestic prescription drug costs by linking them to the lower prices paid in other developed countries, including those in Europe. Launching a drug in a lower-priced European market first could set a disadvantageous price precedent for the much larger U.S. market. Citing this uncertainty, market research firm GlobalData reported a 35% decline in new drug launches across EU markets in the ten months following the U.S. executive order.

Economic and Market Impact

The direct consequence is reduced access to new treatments for European patients. For example, U.S. drugmaker Insmed postponed the German launch of its drug Brunspri, citing the need for clarity on U.S. policy. French health authorities have also noted a sharp drop in early-access applications. This trend creates a complex environment for healthcare policy in Europe and adds a layer of risk for pharmaceutical investors who face unpredictable future earnings.

Conclusion

The ongoing delays highlight a strategic pivot by drugmakers to safeguard their pricing power in the United States. The pace of new medicine introductions in Europe will likely remain suppressed until there is clear and stable legislation regarding international price referencing from the U.S. government.

FAQ

Q: Why are drugmakers delaying new medicine launches in Europe?
A: They are concerned that lower, government-negotiated prices in Europe could be used as a benchmark to force down prices in the more profitable U.S. market.

Q: What is the "most-favored-nation" pricing policy?
A: It is a U.S. proposal to ensure the price paid for prescription drugs is not higher than the lowest price paid among other economically similar nations.

Q: How significant is the decline in European launches?
A: Data indicates new drug launches in the EU fell by approximately 35% in the ten months after the U.S. introduced its international reference pricing proposal.

Source: Investing.com